News, literature and expert perspectives on PCSK9 inhibition in lipid management
AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.
AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.
The ODYSSEY OUTCOMES trial met its primary safety endpoint, showing reduced risk of MACE with alirocumab in patients with ACS compared to placebo, which is dependent on baseline LDL-c levels.
In a substudy of GLAGOV, IVUS-based virtual histology showed regression of coronary atherosclerosis in evolocumab-treated patients, but no changes in plaque composition as compared with placebo.
PCSK9-antibodies reduce non-cholesterol sterols but they do not significantly affect the balance between cholesterol synthesis and absorption, irrespective of cholesterol-lowering pretreatment.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
In patients with an established diagnosis of hypercholesterolemia, tocilizumab blunted the NSTEMI-associated PCSK9 increase and this was strongly correlated with a decrease in neutrophil numbers.
This is a summary of the presentation by John Kastelein, in which he discusses targeting PCSK9 in clinical practice, focusing on issues surrounding prescription of PCSK9 monoclonal antibodies.
This is a summary of the presentation by Jennifer Robinson, in which she explains that the greatest benefit of PCSK9 antibodies can be obtained at higher LDL-c levels, as seen in high-risk populations.
This is a summary of the presentation by Brian Ference, in which he shows data suggesting that PCSK9 inhibitors and statins have biologically and therapeutically equivalent effects on the risk of CVD.
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.